Long-term outcomes of high-risk neuroblastoma patients after immunotherapy
Author Information
Author(s): Simon Thorsten, Hero Barbara, Faldum Andreas, Handgretinger Rupert, Schrappe Martin, Klingebiel Thomas, Berthold Frank
Primary Institution: Children's Hospital, University of Cologne, Cologne, Germany
Hypothesis
Does immunotherapy with antibody ch14.18 improve long-term outcomes in high-risk neuroblastoma patients compared to oral metronomic chemotherapy?
Conclusion
Immunotherapy with MAB ch14.18 may prevent late relapses in high-risk neuroblastoma patients, and metronomic oral maintenance chemotherapy also appears effective.
Supporting Evidence
- The nine-year event-free survival rates were 41 ± 4% for MAB ch14.18 treatment.
- MAB ch14.18 treatment improved long-term outcomes compared to no additional therapy (p = 0.038).
- The overall survival was better in the MAB ch14.18-treated group (9-y-OS 46 ± 4%) compared to NB90 MT (34 ± 5%, p = 0.026).
- Multivariable analysis found better EFS and OS of MAB ch14.18 consolidation compared to no consolidation therapy.
Takeaway
This study looked at kids with a serious cancer called neuroblastoma and found that a special treatment helped them live longer without the cancer coming back.
Methodology
The study analyzed data from 334 stage 4 neuroblastoma patients who received either MAB ch14.18 or oral metronomic chemotherapy, comparing their long-term outcomes.
Potential Biases
Potential biases due to the nonrandomized design and differences in treatment groups.
Limitations
The study is retrospective and nonrandomized, which may affect the reliability of the results.
Participant Demographics
Patients were stage 4 neuroblastoma patients aged one year or older, with a median age of 3.2 years.
Statistical Information
P-Value
p = 0.038
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website